Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 628.73% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.7 million through Dec 2025, up 628.73% year-over-year, with the annual reading at $44.7 million for FY2025, 671.33% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $44.7 million at Telix Pharmaceuticals, up from $6.1 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $44.7 million in Q4 2025, with the low at $6.1 million in Q4 2024.